Bionime Corporation (4737.TW)
TWD 66.0
(-0.9%)
TWD 66.0
(-0.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.3 Billion TWD | 13.95% |
| 2022 | 2.9 Billion TWD | 16.67% |
| 2021 | 2.48 Billion TWD | 3.05% |
| 2020 | 2.41 Billion TWD | 2.41% |
| 2019 | 2.35 Billion TWD | -9.2% |
| 2018 | 2.59 Billion TWD | 13.01% |
| 2017 | 2.29 Billion TWD | 11.54% |
| 2016 | 2.05 Billion TWD | 1.7% |
| 2015 | 2.02 Billion TWD | -38.99% |
| 2014 | 3.31 Billion TWD | -3.87% |
| 2013 | 3.45 Billion TWD | 31.25% |
| 2012 | 2.63 Billion TWD | 49.0% |
| 2011 | 1.76 Billion TWD | 552.49% |
| 2010 | 270.63 Million TWD | 7.74% |
| 2009 | 251.19 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.52 Billion TWD | 3.75% |
| 2024 Q1 | 3.4 Billion TWD | 2.84% |
| 2023 Q3 | 3.12 Billion TWD | 2.46% |
| 2023 FY | 3.3 Billion TWD | 13.95% |
| 2023 Q1 | 2.99 Billion TWD | 3.28% |
| 2023 Q2 | 3.04 Billion TWD | 1.6% |
| 2023 Q4 | 3.3 Billion TWD | 5.99% |
| 2022 Q3 | 2.89 Billion TWD | -1.68% |
| 2022 FY | 2.9 Billion TWD | 16.67% |
| 2022 Q4 | 2.9 Billion TWD | 0.43% |
| 2022 Q2 | 2.93 Billion TWD | 4.39% |
| 2022 Q1 | 2.81 Billion TWD | 13.19% |
| 2021 Q1 | 2.41 Billion TWD | 0.01% |
| 2021 FY | 2.48 Billion TWD | 3.05% |
| 2021 Q3 | 2.53 Billion TWD | 2.49% |
| 2021 Q4 | 2.48 Billion TWD | -1.78% |
| 2021 Q2 | 2.47 Billion TWD | 2.36% |
| 2020 Q1 | 2.21 Billion TWD | -5.91% |
| 2020 Q4 | 2.41 Billion TWD | -2.82% |
| 2020 FY | 2.41 Billion TWD | 2.41% |
| 2020 Q2 | 2.46 Billion TWD | 11.04% |
| 2020 Q3 | 2.48 Billion TWD | 0.86% |
| 2019 Q2 | 2.42 Billion TWD | -0.36% |
| 2019 Q4 | 2.35 Billion TWD | -4.08% |
| 2019 FY | 2.35 Billion TWD | -9.2% |
| 2019 Q1 | 2.43 Billion TWD | -6.11% |
| 2019 Q3 | 2.45 Billion TWD | 1.18% |
| 2018 Q4 | 2.59 Billion TWD | 9.38% |
| 2018 FY | 2.59 Billion TWD | 13.01% |
| 2018 Q3 | 2.37 Billion TWD | 4.8% |
| 2018 Q2 | 2.26 Billion TWD | 2.24% |
| 2018 Q1 | 2.21 Billion TWD | -3.57% |
| 2017 Q3 | 2.46 Billion TWD | 4.92% |
| 2017 Q2 | 2.34 Billion TWD | 22.06% |
| 2017 Q1 | 1.92 Billion TWD | -6.6% |
| 2017 FY | 2.29 Billion TWD | 11.54% |
| 2017 Q4 | 2.29 Billion TWD | -6.75% |
| 2016 Q3 | 1.87 Billion TWD | -8.94% |
| 2016 Q4 | 2.05 Billion TWD | 9.62% |
| 2016 FY | 2.05 Billion TWD | 1.7% |
| 2016 Q1 | 1.82 Billion TWD | -9.87% |
| 2016 Q2 | 2.06 Billion TWD | 13.04% |
| 2015 Q1 | 2.65 Billion TWD | -19.96% |
| 2015 Q2 | 2.77 Billion TWD | 4.38% |
| 2015 Q3 | 2.75 Billion TWD | -0.6% |
| 2015 FY | 2.02 Billion TWD | -38.99% |
| 2015 Q4 | 2.02 Billion TWD | -26.53% |
| 2014 Q3 | 3.38 Billion TWD | -0.38% |
| 2014 Q1 | 3.25 Billion TWD | -5.65% |
| 2014 FY | 3.31 Billion TWD | -3.87% |
| 2014 Q4 | 3.31 Billion TWD | -1.95% |
| 2014 Q2 | 3.39 Billion TWD | 4.32% |
| 2013 FY | 3.45 Billion TWD | 31.25% |
| 2013 Q3 | 3.27 Billion TWD | 7.79% |
| 2013 Q4 | 3.45 Billion TWD | 5.54% |
| 2013 Q1 | 2.83 Billion TWD | 7.69% |
| 2013 Q2 | 3.03 Billion TWD | 7.14% |
| 2012 Q1 | 2.53 Billion TWD | 43.43% |
| 2012 FY | 2.63 Billion TWD | 49.0% |
| 2012 Q4 | 2.63 Billion TWD | 0.02% |
| 2012 Q3 | 2.63 Billion TWD | -3.19% |
| 2012 Q2 | 2.71 Billion TWD | 7.28% |
| 2011 Q1 | 463.63 Million TWD | 71.31% |
| 2011 Q4 | 1.76 Billion TWD | -9.48% |
| 2011 FY | 1.76 Billion TWD | 552.49% |
| 2011 Q3 | 1.95 Billion TWD | 163.21% |
| 2011 Q2 | 741.13 Million TWD | 59.85% |
| 2010 FY | 270.63 Million TWD | 7.74% |
| 2010 Q4 | 270.63 Million TWD | 0.0% |
| 2009 FY | 251.19 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 1.47 Billion TWD | -123.612% |
| Maxigen Biotech Inc. | 131.88 Million TWD | -2407.808% |
| SciVision Biotech Inc. | 533.66 Million TWD | -519.747% |
| Pegavision Corporation | 3.87 Billion TWD | 14.722% |
| Visco Vision Inc. | 1.74 Billion TWD | -89.911% |